We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
Stable funding for work on less glamorous diseases would make the system fairer and more resilient
A sale of consumer health division gives under-fire management cash to play with
German biotech had suffered disappointing results after initial excitement
Bluebell says Jonathan Symonds’ support for executives is ‘inexplicable’
GlaxoSmithKline jab recommended for use in Sub-Saharan Africa and other regions at risk
Pharma group’s ViiV Healthcare looks to work on treatment with dosing intervals of three months or more
Hedge fund is pushing for chief executive Emma Walmsley to reapply for her job
Even with good disclosures and determination, cutting carbon emissions is hard
UK pharma group has teamed up with South Korea’s SK Bioscience on jab that uses its adjuvant technology
Results of animal study show success in tackling several coronavirus variants
Demand for jabs for meningitis, diphtheria and hepatitis recovers after pandemic disruption
Brian McNamara will run business with annual sales of more than £10bn
UK drugmaker seeks to unlock £400m of private investment for site in Stevenage
Pharma group’s board backs Emma Walmsley and announces deal for brain disease drug
Activist hedge fund has outlined little more than polite introduction with air of menace
Activist fund seeks refreshed board to pick who runs UK drugmaker after consumer health spin-off
Emma Walmsley insists she is a ‘change agent’ committed to transforming pharma group
Pharma investors eager to be shot of consumer unit will retain exposure without the upsides
Walmsley has questions to answer at roadshow over direction of pharma group’s future
German drugmaker believes jab could still be used for some age groups or as booster
UK pharma group will pay iTeos Therapeutics up to $2.1bn to collaborate on a tumour drug
Head of division that sells vitamins and toothpaste reveals growth plan for soon-to-be independent business
Pharma group should keep hold of ‘crown jewel’ that has doubled profits in four years
UK group and France’s Sanofi release trial data of Covid jab showing strong immune response
Emma Walmsley says drugmaker’s pipeline shows ‘real progress’
International Edition
